[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335797-105":59,"doc-detail-335797-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","reverse-vaccinology-and-immunoinformatics-strategy-to-screen-oncogenic-proteins-and-development-of-a-multiepitope-peptide-vaccine-targeting-protein-kinases-against-oral-cancer-an-in-silico-study","Reverse Vaccinology and Immunoinformatics Strategy to Screen Oncogenic Proteins and Development of a Multiepitope Peptide Vaccine Targeting Protein Kinases against Oral Cancer - An in-silico Study","","Despite standard therapies and immunotherapies, oral cancer continues to have high mortality, motivating the development of more effective targeted treatments. A reverse vaccinology workflow combined with machine-learning integrated immunoinformatics tools was used to design a multiepitope peptide vaccine. LYN Proto-Oncogene and AKT1 were selected as candidates based on physicochemical, non-allergenic, non-toxic, antigenic properties. Computational epitope screening produced suitable B- and T-cell epitopes, and a vaccine construct used TLR4 agonist as adjuvant, showing strong TLR4 binding and immune activation with IgG/IgM response. The study concludes strong immunogenic potential and dual cellular and humoral immunity against oral cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/reverse-vaccinology-and-immunoinformatics-strategy-to-screen-oncogenic-proteins-and-development-of-a-multiepitope-peptide-vaccine-targeting-protein-kinases-against-oral-cancer-an-in-silico-study/335797/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/reverse-vaccinology-and-immunoinformatics-strategy-to-screen-oncogenic-proteins-and-development-of-a-multiepitope-peptide-vaccine-targeting-protein-kinases-against-oral-cancer-an-in-silico-study/335797.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are new targeted treatments needed for oral cancer?","Question",{"text":112,"@type":113},"Oral cancer has high mortality despite standard therapies, and survival after confirmed diagnosis is less than 50% in reported data, indicating a need for more effective targeted options.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the multiepitope vaccine designed in this study?",{"text":117,"@type":113},"The study used a reverse vaccinology approach combined with machine-learning integrated immunoinformatics tools to screen antigen candidates and select suitable B- and T-cell epitopes, then construct a vaccine using a TLR4 agonist adjuvant.",{"name":119,"@type":110,"acceptedAnswer":120},"Which protein kinases were identified as vaccine candidates, and why were they chosen?",{"text":121,"@type":113},"LYN Proto-Oncogene and AKT1 were identified as promising candidates due to favorable physicochemical properties and predicted non-allergic, non-toxic, and antigenic characteristics, along with their central roles in cancer-related cellular processes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335797,1790993156,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","RESEARCH ARTICLE  \nEditorial Process: Submission:07/13/2024 Acceptance:11/07/2024  \nReverse Vaccinology and Immunoinformatics Strategy to Screen Oncogenic Proteins and Development of a Multiepitope Peptide Vaccine Targeting Protein Kinases against Oral Cancer: An in-silico Study  \nSamir Shaikh 1, Daksh Kunchala 1, Manasi Patel2, Drishti Velecha1, Suresh Prajapati1,2, Reeshu Gupta1,2 *  \nAbstract  \nBackground: Despite standard therapies and immunotherapies, the mortality rate of patients with oral cancer remains high. Therefore, there is a need for more effective and targeted treatments. Multi-epitope vaccines have been developed for various cancers owing to their easy protection and delivery. However, no multi-epitope vaccine has been designed to prevent oral cancer. Methods: In this study, a reverse vaccinology approach, along with various machine-learning integrated immunoinformatics tools, was used to design a multi-epitope peptide vaccine. Results: Using an integrated computational method, LYN Proto-Oncogene and AKT1 were identified as good candidates. Both LYNand AKT1 are protein kinases and plays a central role in regulating various outputs, such as proliferation, differentiation, apoptosis, and migration in cancer. These proteins were selected because of their favorable physicochemical properties, non-allergic, non-toxic, and antigenic nature. Suitable B and T cell epitopes were identified based on their physicochemical characteristics, toxicity, allergenicity, antigenicity, and immunogenicity. A vaccine was constructed using these immune epitopes and TLR4 agonist as an adjuvant. Molecular dynamics simulation suggests strong binding affinity for Toll-like receptor 4. Furthermore, immune simulation studies suggest the activation of immune cells and a strong IgG/IgM response for approximately one year. Conclusion: We propose that the vaccine developed has high immunogenic potential and able to induce both cell mediated and humoral immunity against oral cancer.  \nKeywords: Oral cancer-Reverse vaccinology-multi-peptide vaccine-Molecular dynamics simulation  \nAsian Pac J Cancer Prev, 25 (11), 4067-4080  \nIntroduction  \nOral squamous cell carcinoma that arises from the oral cavity and lips is a major international health problem, with an annual incidence of 389,846 and 188,438 deaths, respectively, according to data from GLOBOCAN 2022. Oral cancer, or cancer of the mouth, is the 16th most prevalent cancer worldwide, with the highest number recorded in Asia (GLOBOCAN 2022). Nevertheless, the number of young patients has increased dramatically, especially those with tongue cancer, in the last 10 years. Reportedly, less than 50% of oral cancer patients survive after a confirmed diagnosis [1] . Therefore, more effective and targeted treatments are required for this life-threatening disease.  \nOral cancer is treated with surgery, chemotherapy, and radiotherapy. Immunotherapy in the field of oral cancer treatment may be the fourth pillar that supports surgery, chemotherapy, and radiotherapy [2] . For  \ninstance, immunostimulants can enhance the production of tumor-specific antibodies, cytokines, and immune cells. The activation of immune cells ultimately aids in the destruction of cancer cells. For example, CD8+ T cells are activated by IL-12, which is released from antigen-presenting cells to kill tumors. Similarly, helper T lymphocytes (Th1 and Th2) play an essential role in the destruction of tumor cells. Th1 cells produce interferon gamma (IFN-γ), which is released from Th1 cells and activates CD8+ T cells, whereas IL-4 is released from Th2 cells and plays an essential role in activating B cells, thereby inducing an antibody-mediated immune response. Therefore, peptide-based vaccines have attracted great interest because they can stimulate both humoral and cell-mediated immune responses [3] . Moreover, these vaccines are considered appropriate because of their ease of protection and delivery to the gut using various strategies.","cbCaifcOY2z7iOQP","https://ap.wps.com/l/cbCaifcOY2z7iOQP","pdf",1731166,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Global burden and unmet need\n## Current treatment landscape and immunotherapy role\n## Peptide vaccine concepts and reverse vaccinology approach","[{\"question\":\"Why are new targeted treatments needed for oral cancer?\",\"answer\":\"Oral cancer has high mortality despite standard therapies, and survival after confirmed diagnosis is less than 50% in reported data, indicating a need for more effective targeted options.\"},{\"question\":\"How was the multiepitope vaccine designed in this study?\",\"answer\":\"The study used a reverse vaccinology approach combined with machine-learning integrated immunoinformatics tools to screen antigen candidates and select suitable B- and T-cell epitopes, then construct a vaccine using a TLR4 agonist adjuvant.\"},{\"question\":\"Which protein kinases were identified as vaccine candidates, and why were they chosen?\",\"answer\":\"LYN Proto-Oncogene and AKT1 were identified as promising candidates due to favorable physicochemical properties and predicted non-allergic, non-toxic, and antigenic characteristics, along with their central roles in cancer-related cellular processes.\"}]","Reverse Vaccinology and Immunoinformatics Strategy to Screen Oncogenic Proteins and Development of a Multiepitope Peptide Vaccine Targeting Protein Kinases against Oral Cancer - An in-silico Study | PDF",1790012365,35]